Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients
- 1Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- 2Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China
- 3School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
A corrigendum on
Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients
by Huang, X., Ran, H., Li, Y., Ma, Q., Ou, C., Qiu, L., Feng, H., and Liu, W. (2022). Front Neurol. 13:961628. doi: 10.3389/fneur.2022.961628
In the published article, an author name was incorrectly written as Yingkia Li. The correct spelling is Yingkai Li.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: myasthenia gravis, leflunomide, low dose prednisone, Th1 cells, Th2 cells, Th17 cells, Th9 cells
Citation: Huang X, Ran H, Li Y, Ma Q, Ou C, Qiu L, Feng H and Liu W (2023) Corrigendum: Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients. Front. Neurol. 14:1179017. doi: 10.3389/fneur.2023.1179017
Received: 03 March 2023; Accepted: 06 March 2023;
Published: 15 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Huang, Ran, Li, Ma, Ou, Qiu, Feng and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huiyu Feng, ZmVuZ2h1aXkmI3gwMDA0MDttYWlsLnN5c3UuZWR1LmNu; Weibin Liu, bGl1d2ImI3gwMDA0MDttYWlsLnN5c3UuZWR1LmNu
†These authors have contributed equally to this work